Skip to main content

Elotuzumab Side Effects

Medically reviewed by Drugs.com. Last updated on Nov 12, 2023.

Applies to elotuzumab: intravenous powder for solution.

Serious side effects of Elotuzumab

Along with its needed effects, elotuzumab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking elotuzumab:

More common

Less common

Other side effects of Elotuzumab

Some side effects of elotuzumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to elotuzumab: intravenous powder for injection.

Dermatologic

Common (1% to 10%): Night sweats[Ref]

Gastrointestinal

Very common (10% or more): Diarrhea (47%), constipation (36%), vomiting (15%), oropharyngeal pain (10%)[Ref]

Hematologic

Very common (10% or more): Lymphopenia (13%)

Frequency not reported: Leukopenia, thrombocytopenia, deep vein thrombosis[Ref]

Hepatic

Frequency not reported: Hypoalbuminemia, elevated alkaline phosphatase[Ref]

Hypersensitivity

Common (1% to 10%): Hypersensitivity

Uncommon (0.1% to 1%): Anaphylactic reaction[Ref]

Metabolic

Very common (10% or more): Decreased appetite (21%), weight loss (14%)

Frequency not reported: Hyperglycemia, hypocalcemia, low bicarbonate, hyperkalemia[Ref]

Musculoskeletal

Very common (10% or more): Pain in extremities (16%)

Common (1% to 10%): Chest pain[Ref]

Nervous system

Very common (10% or more): Peripheral neuropathy (27%), headache (15%)

Common (1% to 10%): Hypoesthesia[Ref]

Ocular

Very common (10% or more): Cataracts (12%)[Ref]

Oncologic

Common (1% to 10%): Invasive second primary malignancies (SPM)[Ref]

Other

Very common (10% or more): Fatigue (62%), pyrexia (37%)[Ref]

Psychiatric

Common (1% to 10%): Altered mood[Ref]

Renal

Common (1% to 10%): Acute renal failure[Ref]

Respiratory

Very common (10% or more): Cough (34%), nasopharyngitis (25%), upper respiratory tract infection (23%), pneumonia (20%)

Common (1% to 10%): Respiratory tract infection, pulmonary embolism[Ref]

Immunologic

Very common (10% or more): Herpes zoster[Ref]

Local

Common (1% to 10%): Infusion related reaction[Ref]

Frequently asked questions

References

1. Cerner Multum, Inc. UK Summary of Product Characteristics.

2. Cerner Multum, Inc. Australian Product Information.

3. Product Information. Empliciti (elotuzumab). Bristol-Myers Squibb. 2015.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.